Abstract
Retinal Pigment Epithelium (RPE) tear is an uncommon but recognized complication of anti-Vascular Endothelial Growth Factor (anti-VEGF) treatment for neovascular age-related macular degeneration. This has predominantly been reported in association with bevacizumab (Avastin), ranibizumab (Lucentis), and pegaptanib (Macugen). Herein, we report a unique case of early RPE tear four days following an intravitreal aflibercept (Eylea) injection. To the best of our knowledge, this describes the earliest RPE tear following intravitreal aflibercept injection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
